Yan Bingbing, Yin Fuqiang, Wang Q I, Zhang Wei, Li L I
Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.
Medical Scientific Research Centre, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China; Key Laboratory of High-Incidence Tumor Prevention and Treatment, Guangxi Medical University, Ministry of Education, Nanning, Guangxi 530021, P.R. China.
Oncol Lett. 2016 Jul;12(1):157-166. doi: 10.3892/ol.2016.4608. Epub 2016 May 18.
The main obstacle to the successful treatment of ovarian cancer is the development of drug resistance to combined chemotherapy. Among all the factors associated with drug resistance, DNA methylation apparently plays a critical role. In this study, we performed an integrative analysis of the 26 DNA-methylated genes associated with drug resistance in ovarian cancer, and the genes were further evaluated by comprehensive bioinformatics analysis including gene/protein interaction, biological process enrichment and annotation. The results from the protein interaction analyses revealed that at least 20 of these 26 methylated genes are present in the protein interaction network, indicating that they interact with each other, have a correlation in function, and may participate as a whole in the regulation of ovarian cancer drug resistance. There is a direct interaction between the phosphatase and tensin homolog (PTEN) gene and at least half of the other genes, indicating that PTEN may possess core regulatory functions among these genes. Biological process enrichment and annotation demonstrated that most of these methylated genes were significantly associated with apoptosis, which is possibly an essential way for these genes to be involved in the regulation of multidrug resistance in ovarian cancer. In addition, a comprehensive analysis of clinical factors revealed that the methylation level of genes that are associated with the regulation of drug resistance in ovarian cancer was significantly correlated with the prognosis of ovarian cancer. Overall, this study preliminarily explains the potential correlation between the genes with DNA methylation and drug resistance in ovarian cancer. This finding has significance for our understanding of the regulation of resistant ovarian cancer by methylated genes, the treatment of ovarian cancer, and improvement of the prognosis of ovarian cancer.
卵巢癌成功治疗的主要障碍是对联合化疗产生耐药性。在所有与耐药性相关的因素中,DNA甲基化显然起着关键作用。在本研究中,我们对26个与卵巢癌耐药性相关的DNA甲基化基因进行了综合分析,并通过包括基因/蛋白质相互作用、生物过程富集和注释在内的全面生物信息学分析对这些基因进行了进一步评估。蛋白质相互作用分析结果显示,这26个甲基化基因中至少有20个存在于蛋白质相互作用网络中,表明它们相互作用、功能相关,可能作为一个整体参与卵巢癌耐药性的调控。磷酸酶和张力蛋白同源物(PTEN)基因与至少一半的其他基因存在直接相互作用,表明PTEN可能在这些基因中具有核心调控功能。生物过程富集和注释表明,这些甲基化基因中的大多数与细胞凋亡显著相关,这可能是这些基因参与卵巢癌多药耐药调控的重要途径。此外,对临床因素的综合分析显示,与卵巢癌耐药性调控相关的基因甲基化水平与卵巢癌预后显著相关。总体而言,本研究初步解释了DNA甲基化基因与卵巢癌耐药性之间的潜在关联。这一发现对于我们理解甲基化基因对耐药性卵巢癌的调控、卵巢癌的治疗以及改善卵巢癌预后具有重要意义。